...
首页> 外文期刊>Journal of Clinical Microbiology >Comparison of the BD Veritor System for Flu A+B with the Alere BinaxNOW Influenza A&B Card for Detection of Influenza A and B Viruses in Respiratory Specimens from Pediatric Patients
【24h】

Comparison of the BD Veritor System for Flu A+B with the Alere BinaxNOW Influenza A&B Card for Detection of Influenza A and B Viruses in Respiratory Specimens from Pediatric Patients

机译:流感A + B的BD Veritor系统与Alere BinaxNOW流感A&B卡用于检测儿科患者呼吸道标本中甲型和乙型病毒的比较

获取原文

摘要

The performance characteristics of two commercially available rapid tests for influenza, the BD Veritor System for Flu A+B (BD) and the Alere BinaxNOW influenza A&B card (BN), were evaluated using 200 frozen clinical specimens collected from January 2011 to June 2012 from pediatric patients. Real-time reverse transcriptase PCR (RT-PCR) was used as the gold standard to evaluate the results obtained by the two different assays. Of the 200 specimens tested, real-time RT-PCR assay detected influenza A or B virus in 116 samples, while BD detected 104 samples and BN detected 84 samples as positive. The overall sensitivity and specificity for detection of both influenza A and B virus in comparison to those of real-time RT-PCR were 89.6% (95% confidence interval [CI], 82.2 to 94.3) and 98.8% (95% CI, 92.6 to 99.9) for BD Veritor and 72.4% (95% CI, 63.2 to 80.0) and 100% (95% CI, 94.5 to 100.0) for BinaxNOW. Workflow analysis indicated that overall processing times for a batch size of 10 specimens were virtually identical between both systems. Overall, these results indicate that the BD Veritor assay was more sensitive than the BinaxNOW assay in detection of influenza A and B viruses in respiratory specimens from pediatric patients.
机译:使用从2011年1月至2012年6月收集的200份冷冻临床标本评估了两种商业上可快速获得的流感快速检测的性能特征,分别是BD Veritor System for Flu A + B(BD)和Alere BinaxNOW A&B卡(BN)。小儿患者。实时逆转录酶PCR(RT-PCR)被用作金标准,以评估通过两种不同测定获得的结果。在测试的200个样本中,实时RT-PCR分析检测到116个样本中的A或B型流感病毒,而BD检测到104个样本,而BN检测到84个样本为阳性。与实时RT-PCR相比,检测甲型和乙型流感病毒的总体敏感性和特异性分别为89.6%(95%置信区间[CI],从82.2到94.3)和98.8%(95%CI,92.6) BD Veritor为99.9%)和BinaxNOW为72.4%(95%CI,63.2至80.0)和100%(95%CI,94.5至100.0)。工作流程分析表明,两个系统之间批量处理10个样本的总处理时间实际上是相同的。总体而言,这些结果表明,在检测儿科患者呼吸道标本中的甲型和乙型流感病毒时,BD Veritor检测比BinaxNOW检测更灵敏。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号